I am a
Home I AM A Search Login

Papers of the Week

Papers: 1 Aug 2020 - 7 Aug 2020

Pharmacology/Drug Development

2020 Jul 31

Pain Ther

Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth.


McAnally H, Bonnet U, Kaye AD
Pain Ther. 2020 Jul 31.
PMID: 32737803.


Recent years have seen a dramatic escalation of off-label prescribing for gabapentin and pregabalin (gabapentinoids) owing in part to generic versions of each being released over the past two decades, but also in part as a response to increasing calls for multimodal and non-opioid pain management strategies. In this context, several recent articles have been published alleging widespread misuse, with speculations on the unappreciated addictive potential of the gabapentinoid class of drugs. Reports of a 1% population-level abuse prevalence stem from a single internet survey in the UK, and the vanishingly small adverse event outcomes data do not support such frequency. In this targeted narrative review, we aim to disabuse pain physicians and other clinicians, pharmacists, and policymakers of both the positive and negative myths concerning gabapentinoid medications.